Perspective Therapeutics

Perspective Therapeutics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Perspective Therapeutics (CATX) as of Oct 21, 2026 is 92.35 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 91.71 % — a change of 0.70% (higher).

FCF Conversion

92.35 %

YoY

0.70%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Perspective Therapeutics is 2025 92.35 % . FCF Conversion Rate (FCF/EBITDA) of Perspective Therapeutics was 2024 91.71 % . It decreases by 0.70% higher compared to the previous year.

The Perspective Therapeutics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
90.28 USD
Jan 1, 2019
113.26 USD
Jan 1, 2020
119.73 USD
Jan 1, 2021
100.94 USD
Jan 1, 2022
111.51 USD
Jan 1, 2023
85.03 USD
Jan 1, 2024
91.71 USD
Jan 1, 2025
92.35 USD
The Perspective Therapeutics FCF Conversion history
YEARFCF ConversionYoY
92.35 %+0.70%
91.71 %+7.86%
85.03 %-23.74%
111.51 %+10.47%
100.94 %-15.69%
119.73 %+5.72%
113.26 %+25.45%
90.28 %-11.14%
101.61 %+9.39%
92.89 %-6.91%
99.78 %+82.12%
54.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Perspective Therapeutics Stock analysis

What does Perspective Therapeutics do? Perspective Therapeutics Inc is a biotechnology company based in Seattle, United States, specializing in radiopharmaceutical development. The firm employs 163 people and focuses on advanced cancer treatments using proprietary technology that leverages the alpha-emitting isotope 212Pb. This approach delivers targeted radiation to cancer cells via specialized peptides, aiming to maximize efficacy while minimizing toxicity. Additionally, the company develops imaging diagnostics to personalize patient care. Its pipeline includes programs for metastatic melanoma and neuroendocrine tumors, which have entered Phase I/IIa clinical trials at academic institutions. Perspective Therapeutics also produces a 212Pb generator to secure essential isotopes for its clinical activities. The company has been listed on the market since May 31, 2002. Perspective Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Perspective Therapeutics stock

FCF Conversion Rate (FCF/EBITDA) of Perspective Therapeutics is 92.35 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Perspective Therapeutics changed from 91.71 % to 92.35 %, representing a 0.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Perspective Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Perspective Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Perspective Therapeutics

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Perspective Therapeutics